Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1997-06-02
1999-08-17
Lee, Howard C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 54, 514 61, 536123, 5361231, 53612313, A61K 3173, A61K 31725, C08B 304, C08B 306
Patent
active
059394030
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to an anti-inflammatory agent, antiallergic agent, immunomodulator, cell differentiation inducer, apoptosis inducer, and a keratan sulfate oligosaccharide which is useful as an active ingredient of these pharmaceuticals.
BACKGROUND ART
Keratan sulfate is a glycosaminoglycan having N-acetyllactosamine as the basic structure which has O-sulfated hydroxyl group at C-6 position of the N-acetylglucosamine residue. Especially, high-sulfated keratan sulfate which further has a sulfated hydroxyl group beside that at C-6 position of N-acetylglucosamine residue in the constitutional disaccharide unit is known to be contained in cartilaginous fishes such as sharks, and cartilage, bone and cornea of mammals such as whale and bovines. As a method for producing a keratan sulfate oligosaccharide which is the degradation product of the keratan sulfate, a method which comprises allowing a keratan sulfate degrading enzyme (keratanase II; Japanese Patent Application Laid-open No. 2-57182) derived from the microorganism belonging to the genus Bacillus to act on keratan sulfate has been reported.
Further, there is a report (Biochemistry, 33, 4836-4846 (1994)) which analyzes 25 kinds of the oligosaccharide fractions obtained by the fractionation of degradation products after degrading keratan sulfate derived from bovine cartilage with keratanase II and infers the structures of the tetrasulfated N-acetyllactosamine tetrasaccharide represented by the following formula (I) (hereinafter also referred to as "keratan sulfate tetrasaccharide (I)"), the trisulfated N-acetyllactosamine pentasaccharide represented by the following formula (II) (hereinafter also referred to as "keratan sulfate pentasaccharide (II)"), the disulfated N-acetyllactosamine disaccharide represented by the following formula (III) (hereinafter also referred to as "keratan sulfate disaccharide (III)"), and the like. glucosamine, Neu represents a neuraminic acid, Ac represents an acetyl group, and 6S represents a 6-O-sulfate ester. And ".about." represents an .alpha.2,3 bond or .alpha.2,6 bond.)
Up to now, however, no reports have appeared concerning efficient mass production of pure keratan sulfate oligosaccharide, especially the keratan sulfate tetrasaccharide (I), the keratan sulfate pentasaccharide (II), and the keratan sulfate disaccharide (III), without contamination of impurities (for example, endotoxin, nucleic acid, protein, protease, other glycosaminoglycans except for keratan sulfate oligosaccharide, and the like). The contamination of such impurities is liable to be a serious defect especially in the case where the keratan sulfate oligosaccharide is used as pharmaceuticals. Furthermore, the pharmacological functions (especially anti-inflammatory function, antiallergic function, immunomodulating function, cell differentiation inducing function, and apoptosis inducing function) of the keratan sulfate oligosaccharide are not known at all.
DISCLOSURE OF THE INVENTION
The present invention has been acomplished from the viewpoint as described above, an object of which is to provide a use of keratan sulfate oligosaccharide without substantial contamination of impurities as anti-inflammatory agents, antiallergic agents, immunomodulators, cell differentiation inducers (hereinafter also reffered to as "differentiation inducers"), or apoptosis inducers.
In order to achieve the above object, the present inventors made an diligent studies on the pharmacological functions of the oligosaccharide which comprises from two to five sugar units, especially disaccharide, tetrasaccharide or pentasaccharide prepared from degradation products which are obtained by degrading high-sulfated keratan sulfate with a keratan sulfate degrading enzyme, and as a result, it has been found that the oligosaccharide described above and the salt thereof have an excellent anti-inflammatory function, antiallergic function, immunomodulating function, cell differentiation inducing function, and apoptosis inducing function. Thus, the present in
REFERENCES:
patent: 4665060 (1987-05-01), Mardh et al.
patent: 4851338 (1989-07-01), Mardh et al.
patent: 5489578 (1996-02-01), Rosen et al.
patent: 5514660 (1996-05-01), Zopf et al.
patent: 5580862 (1996-12-01), Rosen et al.
Brown et al. Eur. J. Biochem, vol. 224(2):281-308 Abstract Only, 1994.
Brown et al. Biochemistry, vol. 33(16):4836-4846 Abstract Only, 1994.
Kobayashi, Masanori: Yamazaki, Fumito: Ito, Yukishige: Ogawa, Tomoya: A Synthetic Approach to Keratan Sulfate: I. Synthesis of Trisulfated glycoteraose, Tetrahedron Letters, vol. 30, No. 34, pp. 4547-4550, 1989.
"The Carbhydrates, Chemistry and Biochemistry" Second Edition, 1970, vol. 11B, Academic Press, editors Ward Pigman, Derek Horton and Anthony Herp.
Asari Akira
Maruyama Hiroshi
Miyauchi Satoshi
Morikawa Kiyoshi
Tawada Akira
Lee Howard C.
Seikagaku Corporation
LandOfFree
Keratan sulfate oligosaccharide fraction and pharmaceutical cont does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Keratan sulfate oligosaccharide fraction and pharmaceutical cont, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Keratan sulfate oligosaccharide fraction and pharmaceutical cont will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-314903